Bi Asset Management Fondsmaeglerselskab A Amgen Inc Transaction History

Bi Asset Management Fondsmaeglerselskab A

$6.11 Billion
Q2 2024

A detailed history of Bi Asset Management Fondsmaeglerselskab A transactions in Amgen Inc stock. As of the latest transaction made, Bi Asset Management Fondsmaeglerselskab A holds 47,125 shares of AMGN stock, worth $14.9 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares

47,125

Previous 212,360 77.81%

Holding current value

$14.9 Million

Previous $60.4 Million 75.61%

% of portfolio

0.24%

Previous 1.14%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$262.75 - $319.31 $43.4 Million - $52.8 Million	-165,235 Reduced 77.81%	47,125 $14.7 Million
Q1 2024 May 03, 2024	BUY	$268.87 - $324.56 $16 Million - $19.3 Million	59,610 Added 39.02%	212,360 $60.4 Million
Q4 2023 Feb 09, 2024	SELL	$255.7 - $288.46 $11.3 Million - $12.7 Million	-44,021 Reduced 22.37%	152,750 $44 Million
Q3 2023 Nov 13, 2023	SELL	$218.65 - $271.46 $375,859 - $466,639	-1,719 Reduced 0.87%	196,771 $52.9 Million
Q2 2023 Aug 03, 2023	BUY	$214.27 - $253.37 $2.36 Million - $2.79 Million	10,995 Added 5.86%	198,490 $44.1 Million
Q1 2023 May 12, 2023	SELL	$225.79 - $275.2 $116,959 - $142,553	-518 Reduced 0.28%	187,495 $45.3 Million
Q4 2022 Feb 13, 2023	BUY	$229.03 - $291.01 $29 Million - $36.8 Million	126,579 Added 206.04%	188,013 $49.4 Million
Q3 2022 Nov 07, 2022	BUY	$224.46 - $253.15 $823,768 - $929,060	3,670 Added 6.35%	61,434 $13.8 Million
Q2 2022 Aug 12, 2022	SELL	$230.71 - $256.74 $1.13 Million - $1.26 Million	-4,894 Reduced 7.81%	57,764 $14.1 Million
Q1 2022 May 11, 2022	SELL	$219.27 - $242.57 $2.51 Million - $2.77 Million	-11,428 Reduced 15.43%	62,658 $15.2 Million
Q4 2021 Feb 02, 2022	BUY	$198.88 - $227.6 $2.96 Million - $3.39 Million	14,875 Added 25.12%	74,086 $16.7 Million
Q3 2021 Nov 09, 2021	SELL	$212.27 - $248.7 $2.48 Million - $2.91 Million	-11,684 Reduced 16.48%	59,211 $12.6 Million
Q2 2021 Aug 06, 2021	SELL	$233.58 - $259.14 $1.16 Million - $1.29 Million	-4,983 Reduced 6.57%	70,895 $17.3 Million
Q1 2021 May 10, 2021	BUY	$221.91 - $258.6 $1.98 Million - $2.3 Million	8,905 Added 13.3%	75,878 $18.9 Million
Q4 2020 Feb 12, 2021	BUY	$216.38 - $257.67 $3.91 Million - $4.66 Million	18,078 Added 36.97%	66,973 $15.4 Million
Q3 2020 Nov 09, 2020	BUY	$234.65 - $260.95 $3.42 Million - $3.81 Million	14,594 Added 42.55%	48,895 $12.4 Million
Q2 2020 Aug 05, 2020	BUY	$197.81 - $242.74 $1.9 Million - $2.33 Million	9,611 Added 38.93%	34,301 $8.09 Million
Q1 2020 May 11, 2020	SELL	$182.24 - $241.7 $4.03 Million - $5.35 Million	-22,120 Reduced 47.25%	24,690 $5.01 Million
Q4 2019 Mar 19, 2020	BUY	$189.21 - $243.2 $1.51 Million - $1.94 Million	7,964 Added 20.5%	46,810 $11.3 Million
Q3 2019 Mar 19, 2020	SELL	$174.11 - $208.62 $22.4 Million - $26.8 Million	-128,667 Reduced 76.81%	38,846 $7.52 Million
Q2 2019 Mar 19, 2020	SELL	$166.7 - $195.41 $2.31 Million - $2.71 Million	-13,857 Reduced 7.64%	167,513 $30.9 Million
Q1 2019 Mar 19, 2020	SELL	$180.87 - $203.88 $1.02 Million - $1.15 Million	-5,625 Reduced 3.01%	181,370 $34.5 Million
Q4 2018 Mar 19, 2020	BUY	$178.4 - $208.25 $2.1 Million - $2.45 Million	11,785 Added 6.73%	186,995 $36.4 Million
Q3 2018 Mar 19, 2020	SELL	$185.29 - $208.89 $633,691 - $714,403	-3,420 Reduced 1.91%	175,210 $36.3 Million
Q2 2018 Mar 19, 2020	BUY	$166.05 - $186.51 $6.68 Million - $7.5 Million	40,230 Added 29.07%	178,630 $33 Million
Q1 2018 Mar 19, 2020	BUY	$169.43 - $198.0 $23.4 Million - $27.4 Million	138,400 New	138,400 $23.6 Million

Others Institutions Holding AMGN

# of Institutions

3,087

Shares Held

417M

Call Options Held

7.19M

Put Options Held

6.13M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $170B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bi Asset Management Fondsmaeglerselskab A, based on Form 13F filings with the SEC.

News

Stay updated on Bi Asset Management Fondsmaeglerselskab A with notifications on news.

Account

Bi Asset Management Fondsmaeglerselskab A Amgen Inc Transaction History